Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 3/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 3/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229935 | 0.87 | PTGES (0.43) | PTGESGRM2CYP2C9CYP2C19HCRTR1 | |
| SCHEMBL25880555 | 0.86 | KLKB1 (0.46) | RECQLCYP2C9CYP2C19LOXLOXL2 | |
| SCHEMBL25880834 | 0.85 | RECQL (0.41) | RECQLPTGESCYP2C9CYP2C19LOX | |
| SCHEMBL25616855 | 0.84 | PTGES (0.43) | PTGESGRM2HCRTR1HCRTR2KLKB1 | |
| SCHEMBL31174780 | 0.83 | RECQL (0.40) | RECQLCYP2C9CYP2C19LOXLOXL2 | |
| SCHEMBL25639248 | 0.83 | RECQL (0.40) | RECQLCYP2C9CYP2C19LOXLOXL2 | |
| SCHEMBL25880976 | 0.82 | RECQL (0.39) | RECQLCYP2C9CYP2C19LOXLOXL2 | |
| SCHEMBL25880602 | 0.81 | LOX (0.57) | RECQLCYP2C9CYP2C19LOXLOXL2 | |
| SCHEMBL8226463 | 0.81 | L3MBTL1 (0.44) | RECQLPTGESGRM2 | |
| SCHEMBL25880800 | 0.81 | RECQL (0.42) | RECQLCYP2C9CYP2C19LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| CN-118525003-A | Novel heteroaryl urea compounds as KV7.2 inhibitors | 伊卡根有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | RECQL 476/4885PTGES 3936/4885GRM2 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.